Regulation of platelet contractility by agonists present across a thrombus

Area of Science:

• Biomedical Engineering
• Cell Biology
• Hematology

Background:

• Cell traction forces are vital for tissue development.
• Platelets form layered thrombi with distinct core and shell structures.
• Thrombus core stability may depend on platelet contractility and microenvironment interactions.

Purpose of the Study:

• To investigate how platelet agonists regulate actomyosin contractility within a thrombus.
• To clarify the spatial regulation of platelet contractility in thrombus formation.

Main Methods:

• In vitro single platelet contractile force measurements.
• Analysis of protease-activated receptor (PAR) signaling pathways.
• Assessment of Rho-associated protein kinase (ROCK) and myosin light chain (MYL) phosphorylation.
• Evaluation of anti-platelet drug efficacy in counteracting clot contraction.

Main Results:

• Thrombin induced significantly higher traction forces (~50%) compared to ADP or collagen-related peptide.
• Combined stimulation of PAR1 and PAR4 maximized platelet contractility.
• Thrombin uniquely triggered sustained ROCK2 and MYL9 phosphorylation via PAR>Gα13>RhoA signaling.
• Thrombin increased MYL9 protein expression and ROCK1 pre-mRNA splicing.
• Anti-platelet drugs inhibited clot contraction in a thrombin concentration-dependent manner.

Conclusions:

• Thrombin plays a key role in maximizing sustained platelet contractility, stabilizing the hemostatic plug.
• The study elucidates the spatiotemporal relationship between thrombin and platelets in hemostasis.
• Combined anti-platelet and anti-coagulation treatments may increase bleeding risk due to impaired clot contraction.